MedTrace Logo

Safety and Efficacy of ACU-D1 in the Treatment of Acne Rosacea

NCT03064438 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-08-23

Study results available
· View outcomes & findings →

Summary

The study evaluated the safety, tolerability, and efficacy of ACCU-D1 when applied twice daily for 12 weeks in adult participants with moderate to severe acne rosacea. Two-third of the participants received ACCU-D1 while one-third of the participants received vehicle control.

Conditions

  • Acne Rosacea

Interventions

DRUG

ACCU-D1

ACCU-D1

DRUG

Vehicle

Placebo Comparator

Sponsors & Collaborators

  • Accuitis, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2018-06-05
Completion
2018-06-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03064438 on ClinicalTrials.gov